Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 146

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 146
---
 rule, Release No. 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses.” Release No.
33-10786 replaces the existing pro forma adjustment criteria with simplified requirements to depict the accounting for the transaction
(“Transaction Accounting Adjustments”) and present the reasonably estimable synergies and other transaction effects that
have occurred or are reasonably expected to occur (“Management’s Adjustments”). The pro forma adjustments reflecting
the consummation of the Business Combination and related transactions are based on certain currently available information and certain
estimates, assumptions and methodologies that management believes are reasonable under the circumstances. The unaudited condensed combined
pro forma adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and
is evaluated. PBAX has elected not to present Management’s Adjustments and will only be presenting Transaction Accounting Adjustments
in the unaudited pro forma condensed combined financial information. There were no pro forma adjustments required to eliminate activities
between the companies.

The unaudited pro forma
condensed combined financial information does not include an income tax adjustment. Upon closing of the Business Combination, it is likely
that the combined company will record a valuation allowance against the total U.S. and state deferred tax assets as the recoverability
of the tax assets is uncertain. The pro forma combined provision for income taxes does not necessarily reflect the amounts that would
have resulted had the combined company filed consolidated income tax returns during the period presented.

The pro forma basic and
diluted earnings per share amounts presented in the unaudited pro forma condensed combined statement of operations are based upon the
number of shares of Common Stock outstanding, assuming the Business Combination and related transactions occurred on the beginning of
the earliest period presented.

Adjustments to Unaudited Pro Forma Condensed Consolidated Combined Balance Sheet:

The adjustments included
in the unaudited pro forma condensed combined balance sheet as of December 31, 2023 are as follows:

| A. | Reflects                                                                                      
 the redemption of 671,285 PBAX shares for $7,524,954, reflecting a redemption price of $11.11 
 per share.                                                                                    |

| B. | Reflects                                                                                     
 the reclassification of PBAX’s remaining 82,047 shares from redeemable to permanent          
 equity and reclassification of the remaining $911,357 from the restricted cash held in trust 
 to cash.                                                                                     |

| C. | Reflects                                                                                          
 the automatic conversion of $